Nuburu Files S-1 for 230M Share Resale After $23.25M Capital Infusion

TL;DR

**Nuburu's S-1 reveals a highly dilutive financing deal, signaling deep financial distress and making it a high-risk bet for any investor.**

AI Summary

Nuburu, Inc. (BURUW) filed an S-1 on December 23, 2025, for the resale of up to 230 million shares of common stock by YA II PN, LTD. This filing follows a significant capital infusion of $23,250,000 from YA II PN, LTD. on December 17, 2025. In exchange for this capital, Nuburu issued a debenture for $25,000,000 and four series of warrants: Series 1 Warrants for 80,000,000 shares at $0.01, Series 2 Warrants for 100,000,000 shares at $0.25, Series 3 Warrants for 25,000,000 shares at $0.375, and Series 4 Warrants for 25,000,000 shares at $0.47. Nuburu will not receive proceeds from the resale of these shares but may benefit from warrant exercises. The company's common stock traded at $0.2152 per share on the NYSE American as of December 19, 2025. Nuburu is classified as an "emerging growth company" and faces high risks, including the need for additional financing and the challenge of achieving commercialization.

Why It Matters

This S-1 filing signals a critical liquidity event for Nuburu, Inc. and its major investor, YA II PN, LTD., potentially diluting existing shareholders significantly with up to 230 million shares entering the market. For investors, the substantial number of warrants issued at low exercise prices (as low as $0.01) suggests a distressed financing scenario, raising concerns about the company's valuation and future capital structure. The competitive landscape for laser technology is intense, and Nuburu's ability to achieve commercialization and secure further financing will be paramount to its survival and growth, impacting employees and customers relying on its long-term viability.

Risk Assessment

Risk Level: high — The risk level is high due to the massive potential dilution from the resale of up to 230 million shares and the issuance of warrants at extremely low exercise prices, such as $0.01 for 80,000,000 shares. The company explicitly states, "Investing in our securities involves a high degree of risk" and highlights its inability to achieve commercialization, indicating significant operational and financial challenges.

Analyst Insight

Investors should exercise extreme caution and consider avoiding BURUW given the substantial dilution risk and the company's stated challenges in achieving commercialization. Current shareholders should evaluate the potential impact of 230 million additional shares on the market and the low warrant exercise prices, which could further depress the stock price.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

$25,000,000

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

Not Disclosed

Key Numbers

• 230 million — Shares of Common Stock (Maximum shares to be resold by YA II PN, LTD., indicating significant potential dilution.)
• $23.25 million — Capital Infusion (Amount received by Nuburu from YA II PN, LTD. on December 17, 2025, crucial for operations.)
• $25 million — Debenture Principal (Aggregate principal amount of the debenture issued to YA II PN, LTD., representing new debt.)
• 80 million — Series 1 Warrant Shares (Shares purchasable at $0.01, highlighting extremely low exercise price and potential dilution.)
• 100 million — Series 2 Warrant Shares (Shares purchasable at $0.25, contributing to the overall dilution potential.)
• $0.2152 — Common Stock Price (Last quoted sale price on December 19, 2025, providing a benchmark for current valuation.)
• December 17, 2025 — Financing Date (Date of the significant financing transaction with YA II PN, LTD.)

Key Players & Entities

• Nuburu, Inc. (company) — Registrant and issuer of securities
• YA II PN, LTD. (company) — Selling Stockholder and provider of capital infusion
• Alessandro Zamboni (person) — Executive Chairman of Nuburu, Inc.
• NYSE American (regulator) — Stock exchange where Nuburu's common stock is traded
• Securities and Exchange Commission (regulator) — Regulatory body for the S-1 filing
• $23,250,000 (dollar_amount) — Aggregate capital infusion from Selling Stockholder
• $25,000,000 (dollar_amount) — Principal amount of the debenture issued
• $0.2152 (dollar_amount) — Last quoted sale price per share on December 19, 2025
• Holland & Hart LLP (company) — Legal counsel for Nuburu, Inc.
• Amy Bowler (person) — Contact at Holland & Hart LLP

FAQ

Risk Factors

• Dependence on YA II PN, LTD. Financing [high — financial]: Nuburu's operations are heavily reliant on the $23.25 million capital infusion from YA II PN, LTD. on December 17, 2025. This financing came with a $25 million debenture and substantial warrant issuances, indicating a significant cost of capital and potential future dilution. The company's ability to achieve commercialization and generate sustainable revenue is critical to servicing this debt and managing the impact of warrant exercises.
• Significant Dilution Potential from Warrants [high — financial]: The issuance of 230 million shares for resale by YA II PN, LTD., coupled with warrants for 250 million shares (Series 1: 80M at $0.01, Series 2: 100M at $0.25, Series 3: 25M at $0.375, Series 4: 25M at $0.47), presents a substantial risk of dilution for existing shareholders. The low exercise prices, particularly for Series 1 and Series 2 warrants, make them highly likely to be exercised if the stock price appreciates, significantly increasing the outstanding share count.
• Commercialization and Market Adoption Challenges [high — operational]: Nuburu faces the significant challenge of achieving commercialization for its products. The success of the company hinges on its ability to scale production, gain market acceptance, and compete effectively in the battery technology sector. Failure to achieve these milestones could jeopardize the company's ability to generate revenue and meet its financial obligations.
• Need for Additional Financing [high — financial]: As an 'emerging growth company' with ongoing commercialization efforts, Nuburu will likely require substantial additional financing beyond the recent YA II PN, LTD. transaction. The company's ability to secure future funding on favorable terms is uncertain and critical for its continued operations and growth.
• Volatile Stock Price and Trading Activity [medium — market]: The common stock traded at $0.2152 on December 19, 2025, indicating a low market valuation. The potential for significant price volatility, especially with the large number of shares available for resale and potential warrant exercises, poses a risk to investors seeking stable returns.

Industry Context

Nuburu operates in the advanced battery materials sector, a rapidly evolving and competitive industry driven by the demand for electric vehicles and energy storage solutions. Key trends include the push for higher energy density, faster charging capabilities, and improved safety. The company faces competition from established players and numerous startups vying for market share and technological leadership.

Regulatory Implications

As an 'emerging growth company,' Nuburu benefits from reduced disclosure requirements under the JOBS Act. However, it remains subject to SEC regulations and exchange listing standards. The S-1 filing itself is a significant regulatory step, ensuring transparency for potential investors in the secondary market.

What Investors Should Do

1. Analyze Dilution Impact
2. Evaluate Commercialization Progress
3. Assess Debt and Future Financing Needs
4. Monitor Stock Price Volatility

Key Dates

• 2025-12-23: Filing of S-1 Registration Statement — Initiates the process for YA II PN, LTD. to resell up to 230 million shares of common stock.
• 2025-12-17: Capital Infusion from YA II PN, LTD. — Nuburu received $23.25 million in exchange for a $25 million debenture and warrants, providing critical operational funding.
• 2025-12-19: Common Stock Trading Price — Nuburu's common stock traded at $0.2152 on the NYSE American, providing a current market valuation benchmark.

Glossary

S-1 Registration Statement

A form filed with the SEC by companies that plan to offer securities to the public. It contains detailed information about the company's business, financial condition, and the securities being offered. (This filing outlines the terms of the resale of shares by YA II PN, LTD. and provides extensive information about Nuburu's financial health and risks.)

Debenture

A type of long-term debt instrument that is not secured by physical assets or collateral. It is backed only by the general creditworthiness of the issuer. (Nuburu issued a $25 million debenture to YA II PN, LTD. as part of the financing, representing a significant debt obligation for the company.)

Warrants

A type of security that gives the holder the right, but not the obligation, to purchase a company's stock at a specified price (the exercise price) within a certain period. (Nuburu issued multiple series of warrants to YA II PN, LTD., which could lead to substantial dilution if exercised, especially given the low exercise prices.)

Emerging Growth Company

A designation under the JOBS Act for companies with less than $1.235 billion in annual gross revenue (as of 2023) that are allowed certain regulatory and disclosure accommodations. (Nuburu's classification as an EGC means it faces fewer regulatory burdens but also highlights its early-stage status and potential need for ongoing capital.)

Resale Prospectus

A prospectus filed by an existing security holder (not the issuer) who intends to sell securities they already own. The issuer typically provides information about itself in the filing. (This S-1 is primarily for the resale of shares by YA II PN, LTD., meaning Nuburu itself is not raising capital directly from this specific offering.)

Year-Over-Year Comparison

This S-1 filing does not provide comparative financial data from a prior year's filing. It focuses on the current financing event with YA II PN, LTD., detailing the capital infusion, the debenture issued, and the extensive warrant and resale share arrangements. The primary risks highlighted are related to this financing structure, potential dilution, and the company's stage of commercialization, rather than year-over-year operational performance changes.

Key Financial Figures

• $0.0001 — Shares") of our common stock, par value $0.0001 per share ("Common Stock"). The share
• $23,250,000 — ge for an aggregate capital infusion of $23,250,000 (the "Purchase Price") from the Selling
• $25,000,000 — ") in the aggregate principal amount of $25,000,000, (ii) warrants (the "Series 1 Warrants"
• $0.01 — rrant Shares") for an exercise price of $0.01 per share, (iii) warrants (the "Series
• $0.25 — rrant Shares") for an exercise price of $0.25 per share, (iv) warrants ("Series 3 War
• $0 — rrant Shares") for an exercise price of $0.375, and (v) warrants (the "Series 4 Wa
• $0.47 — rrant Shares") for an exercise price of $0.47. We are not selling any securities un
• $0.2152 — ck as reported on the NYSE American was $0.2152 per share. We have not listed, nor do w
• $25 million — On December 17, 2025, we completed a $25 million financing transaction (the "Financing")

Filing Documents

• buru-20251223.htm (S-1) — 9624KB
• buru-ex5_1.htm (EX-5.1) — 30KB
• buru-ex23_1.htm (EX-23.1) — 5KB
• buru-exfiling_fees.htm (EX-FILING FEES) — 25KB
• img120293293_0.jpg (GRAPHIC) — 12KB
• img208656848_0.jpg (GRAPHIC) — 23KB
• 0001193125-25-331124.txt ( ) — 38520KB
• buru-20251223.xsd (EX-101.SCH) — 3988KB
• buru-20251223_htm.xml (XML) — 8153KB
• buru-exfiling_fees_htm.xml (XML) — 5KB

Risk Factors

Risk Factors 9 The Financing 27

Use of Proceeds

Use of Proceeds 30 Determination of Offering Price 30 Market for Common Stock and Dividend Policy 30 Our Business 30

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 39 Selling Stockholder 59

Description of Securities to Be Registered

Description of Securities to Be Registered 60

Legal Proceedings

Legal Proceedings 63 Executive Officers, Directors and Director Independence 63

Executive Compensation

Executive Compensation 66 Director Compensation 69

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 71 Certain Relationships and Related Party Transactions 73 Plan of Distribution 83 Legal Matters 84 Experts 84 Where You Can Find More Information 84 Incorporation of Certain Information by Reference 84 Index to Financial Statements F- 1 i Table of Contents About T his Prospectus This prospectus is part of a registration statement on Form S-1 that we filed with the U.S. Securities and Exchange Commission (the "SEC"). Under this registration process, the Selling Stockholder may, from time to time, sell the securities described in this prospectus. We will not receive any proceeds from the sale by the Selling Stockholder of the securities offered in this prospectus. We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part that may contain material information relating to this offering. The prospectus supplement or post-effective amendment may also add, update or change information contained in this prospectus. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or post-effective amendment, you should rely on the prospectus supplement or post-effective amendment, as applicable. Before purchasing any securities, you should carefully read this prospectus, any post-effective amendment, and any applicable prospectus supplement, together with the additional information described under the headings " Where You Can Find More Information ". Neither we nor the Selling Stockholder have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus, any post-effective amendment, or any applicable prospectus supplement prepared by or on behalf of us or to which we have referred you. We and the Selling Stockholder take no responsibility for and can provide no assurance as t

View Full Filing

View this S-1 filing on SEC EDGAR